2021 is one of the most successful years in DAC's history

Company's support helps people in need afford vision care

Practice is participating in Kids With a Vision program

Organizations partner on back-to-school screening campaign

Available for Optomed Handheld Fundus Cameras

The Optomed Polaris and Optomed Halo are now available in the U.S.

Company's contributions help foundation expand reach

Program will enable practices to support the cause of vision in their communities

The in-vitro studies performed in Glauconix's co-culture 3D conventional human outflow model confirm efficacy

Time To Be Bold is a national public service awareness campaign helping the three million Americans 55 or older who are struggling with low vision regain their independence.

An objective, accurate and repeatable way to measure eye alignment

3D Human Tissue Retina Vasculature model provides a new and novel approach to rapidly and efficiently screening numerous therapies for diabetic retinopathy and diabetic macular edema.

Organizations work together to support charitable eye doctors

NovaSight has announced that it is running a large, pivotal multi-center randomized controlled trial to assess the safety and effectiveness of an eye-tracking-based treatment for Amblyopia (Lazy Eye).

Appointment reflects Glauconix Biosciences' expansion of their 3D Human Tissue model platform within the Ophthalmology space and brings their second commercial model closer to market

Company donates to support Essilor Vision Foundation

Today, Tangible Science announces that their long-awaited conditioning solution, Tangible Boost, is now available for purchase for both patients and Eye Care Practitioners.

PPT has taken a leadership role in the global eyecare industry by addressing the question, "How much blue light to filter?" It developed and received a Chinese patent for the Glare Reduction Factor (GRF) that measures the efficacy of a computer lens to reduce glare.

Today, Tangible Science, Inc. has announced that their new conditioning solution Tangible Boost has received FDA clearance and will launch in January 2021.

Patients more likely to achieve 20/20 vision with the new Light Adjustable Lens.

Board-Certified Ophthalmologist Dr. Savak Teymoorian of Harvard Eye Associates assisted in the research and development of new glaucoma drug.

The next generation of dark adaptation testing features a wearable headset and an artificial intelligence-driven onboard technician.

South Carolina's premier ophthalmic provider partners with US Eye to deliver exceptional eye care.

Partnership will help more children receive vision care

New technology simplifies charitable donations for patients and practices

OcuRing™ is a novel drug delivery platform for cataract surgery with potential to eliminate the need for postoperative topical eye drops. $3M DoD award will fund IND-enabling toxicology and manufacturing activities. LayerBio plans to develop OcuRing™ products for multiple cataract surgery-related indications.